`
`
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`
`
`
`
`
` NDAs 21976/S-039 and 202895/S-016
`
`
`
`
`
`
`
`
`
`
`Food and Drug Administration
`
`
` Silver Spring MD 20993
`
`SUPPLEMENT APPROVAL
`
`
`
`
`
`
` Janssen Therapeutics, a Division of Janssen Products, LP
`
`
` Attention: Karen Gerry, BSc.
` Manager, Global Regulatory Affairs
`
`
` 1125 Trenton-Harbourton Rd
`
`
` Titusville, NJ 08560
`
`
`
`Dear Ms. Gerry:
`
`
`
`
`Please refer to your Supplemental New Drug Applications (sNDAs) dated and received February
`
`
`
`6, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA)
`for PREZISTA® (darunavir) tablets, 75 mg, 150 mg, 600 mg, and 800 mg (NDA 21976) and oral
`
`
`
`
`
`solution, 100 mg/mL (NDA 202895).
`
`
`
`
`We acknowledge receipt of your amendments dated March 4, 13, 20, and, 23, 2015.
`
`
`
`
`We also refer to our letter dated January 7, 2015, notifying you, under Section 505(o)(4) of the
`
`
`
`FDCA, of new safety information that we believe should be included in the labeling for the class
`of HIV protease inhibitor drugs, of which PREZISTA® (darunavir) tablets and oral solution are
`
`members. This information pertains to the risk of significant adverse drug-drug interactions
`
`
`
`
`between the psychotropic medication, quetiapine (Seroquel®), and HIV protease inhibitors.
`
`
`
`
`These supplemental new drug applications provide for revisions to the labeling for PREZISTA®
`
`
`
`
`
`
`
`(darunavir) tablets and oral solution, consistent with our January 7, 2015 letter and agreed upon
`
`
`
`
`labeling revisions through electronic mail correspondence dated February 25 and March 11, 13,
`
`and 16, 2015.
`
`
`APPROVAL & LABELING
`
`
`
`
`
`We have completed our review of these supplemental applications, as amended. They are
`approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-
`
`upon labeling text.
`
`CONTENT OF LABELING
`
`
`
`
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the content of
`
`
`
`
`
`labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
`
`automated drug registration and listing system (eLIST), as described at
`
`
`http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content
`
`Reference ID: 3722330
`
`
`
`
`
`
`
`
` NDAs 21976/S-039 and 202895/S-016
`
` Page 2
`
`
`
`
` of labeling must be identical to the enclosed labeling (text for the package insert and text for the
` patient package insert), with the addition of any labeling changes in pending “Changes Being
`
`
`
` Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed
`
`
`
`labeling.
`
`
`
`
`Information on submitting SPL files using eList may be found in the guidance for industry titled
`
`
`
`“SPL Standard for Content of Labeling Technical Qs and As at
`http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U
`
` CM072392.pdf
`
`
`
`The SPL will be accessible from publicly available labeling repositories.
`
`
`
`
`Also within 14 days, amend all pending supplemental applications that includes labeling changes
`
`
`
`for these NDAs, including CBE supplements for which FDA has not yet issued an action letter,
`
`
`
`
`with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the
`
`
`changes approved in these supplemental applications, as well as annual reportable changes and
`
`annotate each change. To facilitate review of your submission, provide a highlighted or marked-
`
`up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy
`
`
`should provide appropriate annotations, including supplement number(s) and annual report
`
`date(s).
`
`
`PROMOTIONAL MATERIALS
`
`You may request advisory comments on proposed introductory advertising and promotional
`
`
`
`
`
`labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory
`
`
`comments, (2) the proposed materials in draft or mock-up form with annotated references, and
`(3) the package insert(s) to:
`
`
`Food and Drug Administration
`
`
`Center for Drug Evaluation and Research
`
`
`Office of Prescription Drug Promotion (OPDP)
`
`
`5901-B Ammendale Road
`
`
`
`Beltsville, MD 20705-1266
`
`
`
`You must submit final promotional materials and package insert(s), accompanied by a Form
`
`
`FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form
`
`
`
`FDA 2253 is available at
`
`http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf.
`Information and Instructions for completing the form can be found at
`
`
`http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For
`
`more information about submission of promotional materials to the Office of Prescription Drug
`
`
`Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.
`
`
`
`All promotional materials that include representations about your drug product must be promptly
`
`
`revised to be consistent with the labeling changes approved in this supplement, including any
`
`
`
`new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials
`
`
`
`
`
`
`Reference ID: 3722330
`
`
`
`
` NDAs 21976/S-039 and 202895/S-016
`
` Page 3
`
`
`
`
` should include prominent disclosure of the important new safety information that appears in the
` revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent
`
`
` to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.
`
`
`
`
`
`
`
`
`REPORTING REQUIREMENTS
`
` We remind you that you must comply with reporting requirements for an approved NDA
`
`
`
` (21 CFR 314.80 and 314.81).
`
`
`
`
`If you have any questions, call Kyong Hyon, Safety Regulatory Project Manager, at (301) 796
`
`0734.
`
`
`
`
`
`
`
`Sincerely,
`
`{See appended electronic signature page}
`
`
`
`Poonam Mishra, M.D., M.P.H.
`
`
`Acting Deputy Director for Safety
`
`Division of Antiviral Products
`
`Office of Antimicrobial Products
`
`Center for Drug Evaluation and Research
`
`
`
`
`
`
`
`
`ENCLOSURE(S):
`
`
`Content of Labeling
`
`
`Reference ID: 3722330
`
`
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`POONAM MISHRA
`03/27/2015
`
`Reference ID: 3722330
`
`